ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
IPO Year: 1987
Exchange: NASDAQ
Website: immucell.com
4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
PORTLAND, Maine, June 21, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that Bryan K. Gathagan has been appointed to its Board of Directors. Mr. Gathagan is the owner and a managing member of broad Thinking, LLC, a management consulting firm and has 25 years of animal health experience. He is a founding member of Animalytix LLC and has served as its Chief Financial and Chief Technology Officer since it began operations in 2010. Prior to Animalytix
PORTLAND, Maine, Nov. 13, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2024. Q3 2024 Highlights: Product sales increased 11% over the comparable quarter in 2023.Product sales increased 51% over the comparable nine-month period in 2023.Product sales increased 46% over the previous trailing twelve-month period ended September 30, 2023. Management's Discussion:"Our preliminary, un
PORTLAND, Maine, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended September 30, 2024 after the market closes on Wednesday, November 13, 2024. The Company is planning to host a conference call the next morning, Thursday, November 14, 2024, at 9:00 AM ET to review the unaudited financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412)
PORTLAND, Maine, Oct. 08, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the third quarter of 2024, which ended September 30, 2024. Preliminary, Unaudited Total Sales Results: 20242023$ Increase % IncreaseDuring the Three-Month Periods Ended September 30,$6.0 million$5.4 million$615,00011% During the Nine-Month Periods Ended September 30,$18.7 million$12.4 million$6.4 million51% During the Twelve-Mont
PORTLAND, Maine, Aug. 13, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended June 30, 2024. Q2 2024 Highlights: Product sales increased 55% versus the comparable quarter in 2023.Product sales increased 82% versus the comparable six-month period in 2023.Product sales increased 48% from the previous trailing twelve-month period ended June 30, 2023. Management's Discussion:"Our preliminary, unaudited
PORTLAND, Maine, Aug. 07, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended June 30, 2024 after the market closes on Tuesday, August 13, 2024. The Company is planning to host a conference call the next morning, Wednesday, August 14, 2024, at 9:00 AM ET to review the unaudited financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (
PORTLAND, Maine, July 09, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the second quarter of 2024, which ended June 30, 2024. Preliminary, Unaudited Total Sales Results: 2024 2023 $ Increase % Increase During the Three-Month Periods Ended June 30,$5.47 million$3.53 million$1.94 million55% During the Six-Month Periods Ended June 30,$12.73 million$6.98 million$5.75 million82% During the Twe
PORTLAND, Maine, June 04, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that its 2024 Annual Meeting of Stockholders (the "Annual Meeting") will be conducted virtually on Thursday, June 13, 2024, at 9:30 AM ET, as previously disclosed in its Proxy Statement filed with the Securities and Exchange Commission ("SEC") on April 26, 2024. The Annual Meeting will be held by remote communication in the form of a telephone conference call and a live audio
PORTLAND, Maine, May 14, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended March 31, 2024. Management's Discussion:"Our preliminary, unaudited product sales for the first quarter of 2024 were first reported on April 9, 2024," commented Michael F. Brigham, President and CEO of ImmuCell. "We have no changes to those figures." Total sales during the three-month period ended March 31, 2024 were 11
PORTLAND, Maine, May 08, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended March 31, 2024 after the market closes on Tuesday, May 14, 2024. The Company is planning to host a conference call the next morning, Wednesday, May 15, 2024, at 9:00 AM ET to review the unaudited financial results. This date has been pushed back five days from the original date of May 10, 2024. Interested parties can access th
PORTLAND, Maine, April 09, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the first quarter of 2024, which ended March 31, 2024. Preliminary, Unaudited Total Sales Results: 20242023$ Increase % IncreaseDuring the Three-Month Periods Ended March 31,$7.3 million$3.4 million$3.8 million111% During the Twelve-Month Periods Ended March 31,$21.3 million$16.0 million$5.3 million33% Total sales during the three-m
10-Q - IMMUCELL CORP /DE/ (0000811641) (Filer)
8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)
8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)
8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)
10-Q - IMMUCELL CORP /DE/ (0000811641) (Filer)
8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)
8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)
8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)
8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)
8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)
PORTLAND, Maine, Nov. 13, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2024. Q3 2024 Highlights: Product sales increased 11% over the comparable quarter in 2023.Product sales increased 51% over the comparable nine-month period in 2023.Product sales increased 46% over the previous trailing twelve-month period ended September 30, 2023. Management's Discussion:"Our preliminary, un
PORTLAND, Maine, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended September 30, 2024 after the market closes on Wednesday, November 13, 2024. The Company is planning to host a conference call the next morning, Thursday, November 14, 2024, at 9:00 AM ET to review the unaudited financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412)
PORTLAND, Maine, Oct. 08, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the third quarter of 2024, which ended September 30, 2024. Preliminary, Unaudited Total Sales Results: 20242023$ Increase % IncreaseDuring the Three-Month Periods Ended September 30,$6.0 million$5.4 million$615,00011% During the Nine-Month Periods Ended September 30,$18.7 million$12.4 million$6.4 million51% During the Twelve-Mont
PORTLAND, Maine, Aug. 13, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended June 30, 2024. Q2 2024 Highlights: Product sales increased 55% versus the comparable quarter in 2023.Product sales increased 82% versus the comparable six-month period in 2023.Product sales increased 48% from the previous trailing twelve-month period ended June 30, 2023. Management's Discussion:"Our preliminary, unaudited
PORTLAND, Maine, Aug. 07, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended June 30, 2024 after the market closes on Tuesday, August 13, 2024. The Company is planning to host a conference call the next morning, Wednesday, August 14, 2024, at 9:00 AM ET to review the unaudited financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (
PORTLAND, Maine, July 09, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the second quarter of 2024, which ended June 30, 2024. Preliminary, Unaudited Total Sales Results: 2024 2023 $ Increase % Increase During the Three-Month Periods Ended June 30,$5.47 million$3.53 million$1.94 million55% During the Six-Month Periods Ended June 30,$12.73 million$6.98 million$5.75 million82% During the Twe
PORTLAND, Maine , June 05, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today provided a regulatory update on the status of its product development initiative for Re-Tain®. As previously disclosed, the Company recently received a Technical Section Incomplete Letter (Incomplete Letter) from the United States Food and Drug Administration (FDA) in response to its third submission of the Chemistry, Manufacturing and Controls (CMC) Technical Section (which is its fif
PORTLAND, Maine, June 04, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that its 2024 Annual Meeting of Stockholders (the "Annual Meeting") will be conducted virtually on Thursday, June 13, 2024, at 9:30 AM ET, as previously disclosed in its Proxy Statement filed with the Securities and Exchange Commission ("SEC") on April 26, 2024. The Annual Meeting will be held by remote communication in the form of a telephone conference call and a live audio
PORTLAND, Maine, May 14, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended March 31, 2024. Management's Discussion:"Our preliminary, unaudited product sales for the first quarter of 2024 were first reported on April 9, 2024," commented Michael F. Brigham, President and CEO of ImmuCell. "We have no changes to those figures." Total sales during the three-month period ended March 31, 2024 were 11
PORTLAND, Maine, May 08, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended March 31, 2024 after the market closes on Tuesday, May 14, 2024. The Company is planning to host a conference call the next morning, Wednesday, May 15, 2024, at 9:00 AM ET to review the unaudited financial results. This date has been pushed back five days from the original date of May 10, 2024. Interested parties can access th
SC 13D - IMMUCELL CORP /DE/ (0000811641) (Subject)
SC 13D/A - IMMUCELL CORP /DE/ (0000811641) (Subject)
SC 13G/A - IMMUCELL CORP /DE/ (0000811641) (Subject)
SC 13G/A - IMMUCELL CORP /DE/ (0000811641) (Subject)
SC 13G/A - IMMUCELL CORP /DE/ (0000811641) (Subject)
With U.S. stock futures trading mixed this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Manchester United Plc. (NYSE:MANU) to report a quarterly loss at 27 cents per share on revenue of $162.92 million before the opening bell, according to data from Benzinga Pro. Manchester United shares gained 1.6% to $16.19 in the after-hours trading session. Kura Sushi USA (NASDAQ:KRUS) posted downbeat results for its third quarter on Tuesday. Kura Sushi shares fell 4.2% to $56.00 in the after-hours trading session. Analysts are expecting PriceSmart, Inc. (NASDAQ:PSMT) to post quarterly earnings at $1.01 per share on revenue of $
ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today provided a regulatory update on the status of its product development initiative for Re-Tain®.
Gainers Jaguar Health (NASDAQ:JAGX) shares rose 25.3% to $0.11 during Tuesday's after-market session. The company's market cap stands at $31.1 million. aTyr Pharma (NASDAQ:LIFE) shares rose 10.45% to $1.9. The company's market cap stands at $128.7 million. Corvus Pharma (NASDAQ:CRVS) shares increased by 7.36% to $1.75. The market value of their outstanding shares is at $85.8 million. ImmuCell (NASDAQ:ICCC) shares increased by 7.27% to $5.6. The market value of their outstanding shares is at $43.4 million. Avenue Therapeutics (NASDAQ:ATXI) shares moved upwards by 6.46% to $0.16. The company's market cap stands at $6.9 million. Xilio Therapeutics (NASDAQ:XLO) shares increased by 5.34% to
Total sales during the twelve-month period ended March 31, 2024 were 33% more than the twelve-month period ended March 31, 2023.
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. • American Electric Power (NASDAQ:AEP) is projected to report quarterly earnings at $1.26 per share on revenue of $5.12 billion. • Quanterix (NASDAQ:QTRX) is expected to report quarterly loss at $0.32 per share on revenue of $29.84 million. • Pinnacle West Capital (NYSE:PNW) is expected to report quarterly loss at $0.13 per share on revenue of $1.12 billion. • Cracker Barrel Old (NASDAQ:CBRL) is expected to report quarterly earnings at $1.37 per share on revenue of $917.33 million. • PAR Technology (NYSE:PAR) is projected to report quart